Apellis Pharmaceuticals, Inc.

    Apellis Pharmaceuticals, Inc.

    NNASDAQ:APLS
    41.03
    USD
    0.00
    (0.00%)
    38.25P/E
    2013 Y
    2014 Y
    2015 Y
    2016 Y
    2017 Y
    2018 Y
    2019 Y
    2020 Y
    2021 Y
    2022 Y
    2023 Y
    2024 Y
    2025 Y
    TTM
    Revenue per Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    3.33
    0.79
    0.71
    3.34
    6.31
    7.96
    8.72
    Basic EPS, GAAP
    -0.22
    -0.6
    -2.57
    -1.5
    -3.68
    -2.34
    -4.9
    -4.59
    -8.84
    -6.15
    -4.45
    -1.6
    0.18
    1.05
    Free Cash Flow per Basic Share
    -0.19
    -0.55
    -1.04
    -1.44
    -3.36
    -2.41
    -3.42
    -2.21
    -6.68
    -4.86
    -5.02
    -0.71
    0.36
    0.3
    Dividend per Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Book Value per Share
    -0.76
    -1.36
    -3.93
    -5.43
    -10.76
    -5.09
    -9.34
    -12.32
    -19.62
    -21.76
    -23.91
    -24.5
    -23.88
    -23.63
    Tangible Book Value per Share
    -0.68
    -1.25
    -2.33
    -3.77
    10.74
    2.96
    0.55
    2.72
    2.35
    1.6
    1.64
    1.84
    2.93
    3.27
    Basic Weighted Avg Shares
    18
    18
    18
    18
    14
    54
    62
    75
    84
    106
    119
    124
    126
    127
    Sales/Revenue/Turnover
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    251
    67
    75
    397
    781
    1,004
    1,105
    Operating Margin (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    -85.27
    -805.67
    -788.38
    -130.39
    -21.11
    5.52
    14.95
    Depreciation Expense
    - -
    - -
    - -
    - -
    - -
    - -
    1
    1
    1
    2
    2
    2
    2
    1
    Net Income, GAAP
    -4
    -11
    -47
    -27
    -51
    -128
    -305
    -345
    -746
    -652
    -529
    -198
    22
    133
    Effective Tax Rate (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    7.14
    1.39
    Profit Margin (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    -137.59
    -1,121.27
    -864.7
    -133.29
    -25.32
    2.23
    12.06
    Working Capital
    5
    13
    35
    24
    175
    185
    307
    789
    692
    552
    519
    603
    691
    745
    LT Debt
    - -
    - -
    - -
    - -
    26
    25
    154
    374
    206
    107
    104
    463
    374
    375
    Total Equity
    5
    13
    35
    24
    149
    161
    34
    205
    199
    170
    195
    229
    370
    415
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    6.67
    21.38
    Return on Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    -2.49
    -6.81
    Return on Common Equity (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -

    Capital Structure

    USD

    •

    in mil. unless spec.
    Sep'25
    Dec'25
    Mar'26
    ST Debt
    101
    101
    101
    LT Borrowings
    361
    362
    362
    LT Finance Leases
    14
    12
    13
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    127
    127
    128
    Market Capitalization
    2,851
    3,164
    5,098

    Working Capital

    USD

    •

    in mil. unless spec.
    Sep'25
    Dec'25
    Mar'26
    Total Current Assets
    991
    1,015
    1,028
    Cash, Cash Equivalents & STI
    479
    466
    405
    Accounts Receivable, Net
    346
    366
    440
    Inventories
    123
    143
    131
    Total Current Liabilities
    280
    324
    283
    Payables & Accruals
    179
    170
    121
    ST Debt
    101
    101
    101
    Deferred Revenue
    - -
    - -
    - -

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    99.75%
    15.32%
    61.96%
    Free Cash Flow
    34.97%
    2.16%
    -151%
    Net Income, GAAP
    25.95%
    -17.81%
    -111.31%
    Sales/Revenue/Turnover
    - -
    98.24%
    28.46%
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2024
    172
    200
    197
    213
    781
    2025
    167
    178
    459
    200
    1,004
    2026
    268
    - -
    - -
    - -
    - -

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2024
    -0.54
    -0.3
    -0.46
    - -
    -1.6
    2025
    -0.74
    -0.33
    1.71
    - -
    0.18
    2026
    0.15
    - -
    - -
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -
    2026
    - -
    - -
    - -
    - -
    - -

    Company Description

    Company Profile APIChatGPT
    Address
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • reuters.com

      Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout

    • gurufocus.com

      Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

    • gurufocus.com

      TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer

    • prnewswire.com

      Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600

    • zacks.com

      Compared to Estimates, Apellis Pharmaceuticals (APLS) Q1 Earnings: A Look at Key Metrics

    • zacks.com

      Apellis Pharmaceuticals, Inc. (APLS) Tops Q1 Earnings and Revenue Estimates

    • globenewswire.com

      $HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—CZNL, HLX, APLS, and SLNO

    • zacks.com

      Biogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A Costs

    • prnewswire.com

      Are CCO, EHAB, APLS, VRE Obtaining Fair Deals for their Shareholders?

    • businesswire.com

      Apellis Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apellis Pharmaceuticals, Inc. - APLS

    • globenewswire.com

      $HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—KZR, FORA, SLNO, and APLS

    • prnewswire.com

      Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders?

    • defenseworld.net

      Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Average Rating of “Hold” by Analysts

    • globenewswire.com

      Shareholder Alert: Ademi LLP investigates whether Apellis Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders

    • feeds.benzinga.com

      Apellis Stock Soars After Biogen Deal, Momentum Score Surges—Here's What Shareholders Get

    • 247wallst.com

      Here Are Thursday’s Top Wall Street Analyst Research Calls: Akamai Technologies, Astra-Zeneca, Brinker, e.l.f. Beauty, Freeport-McMoran, Vale, Wingstop, Wix.com, and More

    • defenseworld.net

      Apellis Pharmaceuticals (NASDAQ:APLS) Hits New 52-Week High – Should You Buy?

    • prnewswire.com

      SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)

    • zacks.com

      Biogen to Acquire Apellis for $5.6B to Strengthen Immunology Portfolio

    • zacks.com

      Apellis Pharmaceuticals (APLS) Moves 135.4% Higher: Will This Strength Last?